AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi
